A study comparing drug-eluting stents made by Biotronik, Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) found no statistically significant difference on target vessel failure or stent thrombosis after three years.
The 3,514-patient Bio-Resort trial compared Biotronik’s Orsiro biodegradable sirolimus-eluting stent, Medtronic’s thin-strut zotarolimus-eluting Resolute Integrity stent and the Synergy biodegradable everolimus-eluting stent.
Three-year results for some 3,393 of the trial’s subjects, published in the Journal of the American Medical Assn., showed TVF rates of 8.5% for the Orsiro stent, 10.0% for Resolute Integrity and 8.8% for the Synergy device. Rates of cardiac death, target vessel myocardial infarction and target vessel revascularization were similar between the three cohorts, according to the study. There were no statistically significant differences in repeat revascularization rates from one to three years and definite or probable stent thrombosis rates were similarly low for all three devices (1.1% for Orsiro and Synergy and 0.9% for Resolute Integrity).
“Despite substantial differences in stent backbone and polymer coating, all three DES showed favorable three-year safety and efficacy in all comers, without significant between-stent differences. Further follow-up is required to definitely answer the question of whether one stent might improve clinical outcomes at a later stage,” the study’s authors wrote.
